DEF 14A: Aquestive Therapeutics Sets Date for 2024 Annual Stockholders Meeting

Aquestive Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, to vote on director elections, executive compensation, and auditor ratification.

Summary

• Aquestive Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 20, 2024, at 9:30 a.m. Eastern Time, in a virtual-only format.
• Stockholders of record as of April 22, 2024, are entitled to vote on several key proposals.
• The proposals include the election of three Class III directors (Santo J. Costa, Julie Krop, M.D., and Marco Taglietti, M.D.), an advisory vote on executive compensation, an advisory vote on the frequency of future say-on-pay votes, and the ratification of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting for the election of the director nominees, for the approval of executive compensation, for a frequency of every one year for future advisory votes on executive compensation, and for the ratification of KPMG LLP.
• The company will begin mailing a Notice of Internet Availability of Proxy Materials on or about April 26, 2024.
• As of the record date, 91,038,532 shares of common stock were outstanding and entitled to vote.
• The Board consists of eight members, seven of whom are independent directors.
• Abigail L. Jenkins was appointed to the Board as a Class II director in April 2024, increasing the board size from seven to eight members.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a slightly positive tone due to management's expressed excitement about the future.

Positives

• The Board of Directors is composed of a majority of independent directors, ensuring strong corporate governance.
• Stockholders have the opportunity to provide input on executive compensation through advisory votes.
• The company is committed to transparency by providing access to proxy materials via the internet.
• The company has an equity grant policy to ensure fair and consistent equity compensation practices.
• The company has adopted a related person transaction policy to ensure fair dealings.

Risks

• The advisory vote on executive compensation is non-binding, meaning the Board is not obligated to act on the outcome.
• The company is a smaller reporting company, which means it has reduced disclosure obligations compared to other issuers.
• The company's insider trading policy prohibits directors, officers and employees from hedging or pledging company securities.

Future Outlook

The company remains focused on advancing its proprietary products in 2024 and is excited about future opportunities.

Management Comments

• Daniel Barber, President and CEO, expressed pleasure with the company's accomplishments during the past year and excitement for future opportunities.
• The Board believes that building a cohesive board is an important goal.
• The Board believes that the classified Board structure is appropriate for the Company at this time.

Industry Context

The document does not explicitly discuss the broader industry context, but it mentions that the company operates in a highly competitive and continually changing market.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards.
• Executive compensation is determined by the Compensation Committee based on comparable positions in the market and the historical compensation levels of our executives, each NEOs performance as compared to our expectations and objectives, and our desire to motivate our executives to achieve shortand long-term results that are consistent with our business strategies and objectives.
• The base salary rates are based upon the recommendations and competitive analysis provided by Aon and are generally consistent with or slightly below the market 50th percentile range assessed by Aon although compensation for individual NEOs may be above or below the median based on experience, scope of position and individual performance.

Management Changes

Related Party Transactions

• The company has granted certain registration rights to directors and officers.
• In connection with a Securities Purchase Agreement entered into by the Company dated June 6, 2022, pursuant to which the Company issued pre-funded warrants and common stock warrants as part of a capital funding program, on June 8, 2022 each of Mr. Barber, Ms. Braender, Mr. Schobel and certain other executive officers participated and were given the right to buy shares of Company common stock at a price equal to $1.09 per share, and also received a warrant for the same number of purchased shares with a warrant exercise price equal to $0.96 per share; the number of shares purchased (and corresponding number of warrants received) were: Mr. Barber, 91,743; Ms. Braender, 13,761; and Mr. Schobel, 45,871.

Stakeholder Impact

• Shareholders have the opportunity to vote on key company matters.
• Executive compensation decisions impact the alignment of management's interests with shareholder value.
• The selection of an independent auditor ensures the integrity of financial reporting.

Next Steps

• Stockholders should review the proxy materials and vote their shares before the Annual Meeting.
• The company will announce preliminary voting results at the Annual Meeting and file final results with the SEC within four business days.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, KPMG, Corporate Governance, Aquestive Therapeutics